Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany
Department of Pneumology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Anticancer Res. 2020 Jun;40(6):3097-3108. doi: 10.21873/anticanres.14291.
BACKGROUND/AIM: C-C motif chemokine ligand 18 (CCL18) is overexpressed in the microenvironment of tumors, promotes invasion and metastasis and is thus important for the therapeutic outcome of many tumor entities. The Gs-coupled seven-transmembrane receptor GPR30 is known as both a CCL18 and an estrogen receptor; its activation by estradiol leads to a transactivation of membrane-tethered pro-heparin-binding EGF-like growth factor and the MAPK/ERK pathway. We examined whether this signaling pathway remains the same under CCL18 stimulation, as opposed to estradiol stimulation.
We investigated the effects of CCL18 on the lung cancer cell line A549, that show low GPR30 expression and the breast cancer cell lines MCF-7, that has high GPR30 expression and MDA-MB-231. These cells were stimulated in different media with CCL18 and then analyzed by qPCR, In-Cell Western®, western blot and ELISA.
Many similarities on the effect of CCL18 on the already known estradiol-activated signaling pathway via the G protein-coupled estrogen receptor GPR30 were identified. GPR30 is involved in the expression of matrix metalloproteinases (MMPs), which may play a role in the transactivation of ERK-1/-2 via the cleavage of membrane-bound HB-EGF, via Src-related tyrosine kinases and Gβγ-subunits. With increasing CCL18 concentration, the expression of MMP7 decreased in A549 cells. With decreasing estrogen content of the medium, there was an increasing effect of CCL18 on the inhibition of the relative expression of MMP7. Inhibition of GPR30 with G15 also resulted in a decrease in the relative expression of MMP7, irrespective of the subsequent stimulation with CCL18. This is a rather unexpected result, because the estrogen estradiol and CCL18 both activate GPR30. MCF-7 cells which express more GPR30 did not show any dependence of the relative MMP7 expression on CCL18 except in estrogen-free FCS medium. CCL18 induced an increased relative ERK activation in In-Cell western (ICW) at A549 cells. Stimulation with CCL18 caused decreased ERK activation with simultaneous inhibition of adenylate cyclase in MCF-7. However, stimulation with CCL18 and simultaneous inhibition of cyclooxygenase in MCF-7 resulted in increased ERK activation. In A549, stimulation with CCL18 and co-incubation with dbcAMP resulted in decreased ERK activation in both ICW and Western blot.
In summary, the Gs-coupled receptor GPR30 plays an important role in the signaling pathway of CCL18. CCL18 and estradiol may not lead to the same signaling pathway after activating GPR30.
背景/目的:C-C 基序趋化因子配体 18(CCL18)在肿瘤微环境中过度表达,促进侵袭和转移,因此对许多肿瘤实体的治疗结果很重要。与雌激素受体结合的 G 蛋白偶联七跨膜受体 GPR30 被认为既是 CCL18 又是雌激素受体;其被雌二醇激活后,导致膜结合肝素结合表皮生长因子样生长因子的转激活和 MAPK/ERK 途径。我们研究了在 CCL18 刺激而非雌二醇刺激下,这种信号通路是否仍然相同。
我们研究了 CCL18 对低 GPR30 表达的肺癌细胞系 A549 和高 GPR30 表达的乳腺癌细胞系 MCF-7 和 MDA-MB-231 的影响。这些细胞在不同的培养基中用 CCL18 刺激,然后通过 qPCR、细胞内西方印迹法、western blot 和 ELISA 进行分析。
许多相似之处被确定为 CCL18 通过 G 蛋白偶联雌激素受体 GPR30 对已经知道的雌二醇激活的信号通路的影响。GPR30 参与基质金属蛋白酶(MMPs)的表达,这可能通过膜结合 HB-EGF 的切割、Src 相关酪氨酸激酶和 Gβγ 亚基在 ERK-1/-2 的转激活中发挥作用。随着 CCL18 浓度的增加,A549 细胞中 MMP7 的表达减少。随着培养基中雌激素含量的降低,CCL18 对 MMP7 相对表达的抑制作用增加。用 G15 抑制 GPR30 也导致 MMP7 的相对表达减少,而不管随后是否用 CCL18 刺激。这是一个相当出乎意料的结果,因为雌激素雌二醇和 CCL18 都激活 GPR30。表达更多 GPR30 的 MCF-7 细胞除了在不含雌激素的 FCS 培养基中外,对相对 MMP7 表达没有任何依赖于 CCL18 的作用。CCL18 在 A549 细胞中的 In-Cell Western(ICW)中诱导相对 ERK 激活增加。CCL18 刺激导致 MCF-7 中的 ERK 激活减少,同时抑制腺苷酸环化酶。然而,在 MCF-7 中同时抑制环氧化酶和刺激 CCL18 导致 ERK 激活增加。在 A549 中,用 CCL18 刺激并与 dbcAMP 共孵育导致 ICW 和 Western blot 中 ERK 激活减少。
总之,G 蛋白偶联受体 GPR30 在 CCL18 的信号通路中发挥重要作用。CCL18 和雌二醇在激活 GPR30 后可能不会导致相同的信号通路。